Profile data is unavailable for this security.
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
- Revenue in USD (TTM)0.00
- Net income in USD-292.19m
- Incorporated2017
- Employees168.00
- LocationZentalis Pharmaceuticals Inc1359 Broadway, Suite 801NEW YORK 10018United StatesUSA
- Phone+1 (212) 433-3791
- Fax+1 (302) 655-5049
- Websitehttps://www.zentalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CARGO Therapeutics Inc | 0.00 | -98.15m | 719.56m | 116.00 | -- | 1.86 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 732.99m | 284.00 | -- | 3.60 | -- | 9.06 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Zentalis Pharmaceuticals Inc | 0.00 | -292.19m | 779.50m | 168.00 | -- | 1.78 | -- | -- | -4.56 | -4.56 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -50.65 | -47.40 | -57.28 | -54.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 780.70m | 24.00 | -- | 3.38 | -- | 26,023.25 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Tango Therapeutics Inc | 36.53m | -101.74m | 782.25m | 140.00 | -- | 2.96 | -- | 21.42 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -71.58m | 783.71m | 46.00 | -- | 2.82 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| 89bio Inc | 0.00 | -142.19m | 785.60m | 70.00 | -- | 1.43 | -- | -- | -2.01 | -2.01 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -35.86 | -45.50 | -38.49 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0442 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Regenxbio Inc | 90.24m | -263.49m | 787.63m | 344.00 | -- | 2.27 | -- | 8.73 | -6.03 | -6.03 | 2.06 | 7.08 | 0.1283 | -- | 3.41 | 262,331.40 | -37.45 | -16.75 | -45.96 | -19.08 | 58.76 | 78.27 | -291.99 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 793.64m | 49.00 | -- | 3.18 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Viridian Therapeutics Inc | 314.00k | -237.73m | 797.15m | 96.00 | -- | 2.91 | -- | 2,538.69 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| National Research Corporation | 148.58m | 30.96m | 801.85m | 435.00 | 26.75 | 16.62 | 21.75 | 5.40 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Eyepoint Pharmaceuticals Inc | 46.02m | -70.80m | 805.27m | 121.00 | -- | 2.98 | -- | 17.50 | -1.84 | -1.84 | 1.18 | 5.43 | 0.1719 | 1.36 | 5.64 | 380,314.10 | -26.44 | -40.44 | -32.35 | -47.79 | 89.93 | 83.45 | -153.84 | -186.23 | 5.39 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Relay Therapeutics Inc | 25.55m | -341.97m | 807.41m | 323.00 | -- | 1.04 | -- | 31.61 | -2.79 | -2.79 | 0.2095 | 5.90 | 0.0263 | -- | 9.79 | 79,089.78 | -35.19 | -28.55 | -36.97 | -29.54 | -- | -- | -1,338.66 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 816.25m | 487.00 | -- | 1.16 | -- | 8.96 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 829.01m | 85.00 | -- | 1.82 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| USANA Health Sciences, Inc. | 921.01m | 63.79m | 830.04m | 1.80k | 13.08 | 1.66 | 10.85 | 0.9012 | 3.30 | 3.30 | 47.61 | 25.99 | 1.50 | 2.75 | -- | 511,672.20 | 10.38 | 16.23 | 13.20 | 21.75 | 80.82 | 81.42 | 6.93 | 8.96 | 3.00 | -- | 0.0016 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
Data as of Apr 26 2024. Currency figures normalised to Zentalis Pharmaceuticals Inc's reporting currency: US Dollar USD
85.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 31 Dec 2023 | 13.96m | 19.67% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 11.56m | 16.29% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 9.65m | 13.59% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.19m | 7.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.42m | 6.23% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.28m | 6.04% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.61m | 5.09% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.85m | 4.01% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 2.82m | 3.97% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 2.34m | 3.30% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
